Arcutis Biotherapeutics delivered substantial revenue expansion in 2025, with fourth-quarter net product revenue from ZORYVE (roflumilast) reaching $127.5 million, representing an 84% year-over-year increase. Full-year 2025 revenues totaled $372.1 million, marking 123% growth compared to the prior year. The company achieved a significant operational milestone by reaching positive operating cash flow during the period, underscoring improved financial efficiency as commercialization efforts advance.
Building on its commercial momentum, Arcutis raised its 2026 revenue guidance to a range of $480-495 million, signaling continued confidence in market demand for its dermatology portfolio. The guidance elevation reflects expectations for sustained ZORYVE adoption across multiple therapeutic indications. To support this growth trajectory, the company is expanding its dermatology sales force while assuming direct responsibility for commercialization efforts in the pediatric and primary care segments, allowing for more targeted market penetration in these channels.
The company also reported positive interim data from a Phase 2 clinical trial evaluating ZORYVE in pediatric atopic dermatitis, providing a foundation for potential label expansion and broader patient population reach. These clinical and commercial developments position Arcutis to capitalize on growing market opportunities within the dermatological therapeutics sector.